Corcept Therapeutics Incorporated

Report azionario NasdaqCM:CORT

Capitalizzazione di mercato: US$7.9b

Corcept Therapeutics Gestione

Criteri Gestione verificati 2/4

Corcept Therapeutics Il CEO è Joseph Belanoff, nominato in Jan1999, e ha un mandato di 27.42 anni. la retribuzione annua totale è $ 15.30M, composta da 7.7% di stipendio e 92.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.67% delle azioni della società, per un valore di $ 210.13M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.6 anni e 24.7 anni.

Informazioni chiave

Joseph Belanoff

Amministratore delegato

US$15.3m

Compenso totale

Percentuale dello stipendio del CEO7.73%
Mandato del CEO27.4yrs
Proprietà del CEO2.7%
Durata media del management5.6yrs
Durata media del Consiglio di amministrazione24.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Aggiornamento della narrazione • Jun 06

CORT: Ovarian Cancer Data And Cushing’s Resubmission Will Drive Future Upside

Corcept Therapeutics' updated analyst price target has increased to $88.00 from $73.40, reflecting analysts' focus on recent price target revisions associated with the relacorilant NDA resubmission and the launch of Lifyorli in ovarian cancer. Analyst Commentary Recent Street research around Corcept Therapeutics centers on two main themes, the relacorilant regulatory path and the commercial opportunity for Lifyorli in ovarian cancer, with both feeding directly into updated valuation work.
Aggiornamento della narrazione • May 11

CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside

Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.
Seeking Alpha • May 04

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

Summary Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint. CORT 2026 revenue guidance was raised to $950–$1,050 million, driven by strong Lyforli uptake and robust Korlym sales, though risks include EU approval uncertainty and potential pricing pressures. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 25

CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback

Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.
Aggiornamento della narrazione • Apr 11

CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds

Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.
Aggiornamento della narrazione • Mar 27

CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk

Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.
Aggiornamento della narrazione • Mar 10

CORT: Future Generic Ruling And Oncology Data Will Drive Upside

Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.
Aggiornamento della narrazione • Feb 24

CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside

Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.
Aggiornamento della narrazione • Feb 09

CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside

Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.
Aggiornamento della narrazione • Jan 26

CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside

Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.
Aggiornamento della narrazione • Jan 10

CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside

Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.
Articolo di analisi • Jan 01

The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%

Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...
Aggiornamento della narrazione • Dec 17

CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks

Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.
Articolo di analisi • Oct 07

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Joseph Belanoff rispetto agli utili di Corcept Therapeutics?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

US$47m

Dec 31 2025US$15mUS$1m

US$98m

Sep 30 2025n/an/a

US$105m

Jun 30 2025n/an/a

US$132m

Mar 31 2025n/an/a

US$133m

Dec 31 2024US$10mUS$1m

US$140m

Sep 30 2024n/an/a

US$140m

Jun 30 2024n/an/a

US$125m

Mar 31 2024n/an/a

US$117m

Dec 31 2023US$9mUS$1m

US$105m

Sep 30 2023n/an/a

US$91m

Jun 30 2023n/an/a

US$94m

Mar 31 2023n/an/a

US$94m

Dec 31 2022US$7mUS$896k

US$101m

Sep 30 2022n/an/a

US$117m

Jun 30 2022n/an/a

US$113m

Mar 31 2022n/an/a

US$112m

Dec 31 2021US$11mUS$844k

US$113m

Sep 30 2021n/an/a

US$106m

Jun 30 2021n/an/a

US$98m

Mar 31 2021n/an/a

US$99m

Dec 31 2020US$6mUS$770k

US$106m

Sep 30 2020n/an/a

US$109m

Jun 30 2020n/an/a

US$114m

Mar 31 2020n/an/a

US$106m

Dec 31 2019US$5mUS$708k

US$94m

Compensazione vs Mercato: La retribuzione totale di Joseph ($USD 15.30M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 8.38M ).

Compensazione vs guadagni: La retribuzione di Joseph è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Joseph Belanoff (69 yo)

27.4yrs
Mandato
US$15,303,551
Compensazione

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Joseph Belanoff
Co-Founder27.4yrsUS$15.30m2.67%
$ 210.1m
Atabak Mokari
CFO & Treasurer5.3yrsUS$6.14m0.015%
$ 1.2m
Sean Maduck
President of Endocrinology10.2yrsUS$6.21m0.11%
$ 8.8m
William Guyer
Chief Development Officer4.8yrsUS$6.34m0.0037%
$ 292.1k
Gary Robb
Chief Business Officer & Secretary12.4yrsUS$6.38m0.094%
$ 7.4m
Joseph Lyon
Chief Technology & Accounting Officer5.9yrsNessun dato0.0066%
$ 515.6k
Hazel Hunt
Chief Scientific Officer5.9yrsUS$3.11m0.24%
$ 18.7m
Amy Flood
Chief Human Resources & Communications Officer4.9yrsNessun datoNessun dato
Monica Tellado
President of Emerging Markets2.6yrsNessun datoNessun dato
Roberto Vieira
President of Oncology2.4yrsNessun datoNessun dato
5.6yrs
Durata media
55.5yo
Età media

Gestione esperta: Il team dirigenziale di CORT è esperto e expertise (durata media dell'incarico 5.6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Joseph Belanoff
Co-Founder27.4yrsUS$15.30m2.67%
$ 210.1m
George Baker
Independent Director27.4yrsUS$768.00k5.17%
$ 407.0m
David Mahoney
Independent Director21.9yrsUS$784.50k1.2%
$ 94.1m
Charles Nemeroff
Member of Scientific Advisory Boardno dataNessun datoNessun dato
James Wilson
Independent Chairman27.4yrsUS$1.29m1.4%
$ 110.3m
Florian Holsboer
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Bruce McEwen
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Ned Kalin
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Edo Kloet
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Gregg Alton
Independent Director6.3yrsUS$787.00k0%
$ 0
K. Ranga Krishnan
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Kimberly Park
Independent Director6.8yrsUS$764.99k0%
$ 0
24.7yrs
Durata media
70.5yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CORT è composto da personale esperto e esperto (durata media dell'incarico 24.7 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/09 11:32
Prezzo dell'azione a fine giornata2026/06/09 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Corcept Therapeutics Incorporated è coperta da 18 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
David BuckB. Riley Securities, Inc.